Adjuvant chemotherapy stands as a vital ally in the battle against cancer, employed post-primary treatments to eliminate residual cancer cells and thwart potential recurrence. Its pivotal role lies in targeting minuscule disease remnants undetectable through conventional means, effectively reducing the likelihood of metastasis or relapse. Customized to each patient's cancer type and stage, this supplementary therapy significantly bolsters survival rates. However, its efficacy is tempered by notable side effects like nausea and fatigue, prompting the ongoing pursuit of tailored treatment approaches that optimize outcomes while mitigating adverse reactions. As research strides forward, refining adjuvant chemotherapy protocols remains pivotal, ensuring that each dose strikes the delicate balance between efficacy and preserving patients' quality of life.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China